UCSD John B. West Distinguished Lecture Series, Sponsored by MediPines | Featuring Nobel Laureate Dr. Gregg L Semenza

MediPines, the pioneering market leader in non-invasive pulmonary gas exchange technology, and maker of AGM100, will sponsor this year’s annual UCSD John B. West Distinguished Lecture event featuring Nobel Laureate Gregg L. Semenza, MD, PhD.

The lecture, titled “Hypoxia-Inducible Factors in Physiology and Medicine,” will take place on August 7, 2023 at noon pacific time via livestream from UCSD.

“We’re honored to be hosting the esteemed Dr. Semenza, a pioneer and expert on studying how cells adapt to changing oxygen levels and molecular mechanisms of oxygen homeostasis,” said Dr. Jason Yuan, Professor and Director, Section of Physiology of the Division of Pulmonary, Critical Care and Sleep Medicine at UCSD. Dr. Yuan is a co-author of Ganong’s Review of Medical Physiology.

“We’re delighted to have Dr. Gregg L Semenza speak on this very important topic in medicine. He is an outstanding example of a physician scientist whose work has set the bedrock for numerous clinical innovations,” said MediPines CEO, Steve Lee, who co-invented non-invasive pulmonary gas exchange monitoring technology, AGM100, with Dr. West.

Dr. Semenza, the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins University, was awarded the Nobel Prize in Physiology or Medicine, with William G. Kaelin, Jr. and Peter J. Ratcliffe in 2019 for his groundbreaking discovery of the hypoxia-inducible factor (HIF) protein. His research on molecular mechanisms of oxygen homeostasis and oxygen sensing has generated more than 500 research articles.

After introductory notes by Zea Borok, MD (Chair of Medicine, UCSD); Jess Mandel, MD, (Chief of Pulmonary, Critical Care and Sleep Medicine, UCSD); John B. West, MD, PhD, DSc (Emeritus Professor of Medicine and Physiology at UCSD); and Steve Lee (CEO of MediPines), Dr. Semenza will deliver his lecture. After the presentation and a brief Q&A session, Dr. West will present a plaque and honorarium to Dr. Semenza.

As part of the program, there will also be a clinical presentation from a UCSD physician-scientist after the lecture.

Registration for the event can be accessed here: https://medipines.com/jbwlecture2023

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version